NDAORALTABLET
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
PHYRAGO (dasatinib) by Dr. Reddy's Laboratories is dasatinib, at nanomolar concentrations, inhibits the following kinases: bcr-abl, src family (src, lck, yes, fyn), c-kit, epha2, and pdgfrβ. Approved for chronic myelogenous leukemia, acute lymphoblastic leukemia. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHYRAGO (dasatinib) is an oral tyrosine kinase inhibitor that targets BCR-ABL and SRC family kinases, approved for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It overcomes imatinib resistance through multi-kinase inhibition and ability to bind multiple ABL kinase conformations.
Growth14.7 years to LOE
Early-stage generic entry in growth phase; commercial teams will focus on market penetration against established branded competitors with physician switching strategies.
Mechanism of Action
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines…
Indications (2)
Worked on PHYRAGO at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.